TW200605881A - Substantially pure 2-{[2-(2-methylamino-pyrimidin-4-yl)-1H-indole-5-carbonyl]-amino}-3-(phenylpyridin-2-yl-amino)-propionic acid as an IκB kinase inhibitor - Google Patents

Substantially pure 2-{[2-(2-methylamino-pyrimidin-4-yl)-1H-indole-5-carbonyl]-amino}-3-(phenylpyridin-2-yl-amino)-propionic acid as an IκB kinase inhibitor

Info

Publication number
TW200605881A
TW200605881A TW094115316A TW94115316A TW200605881A TW 200605881 A TW200605881 A TW 200605881A TW 094115316 A TW094115316 A TW 094115316A TW 94115316 A TW94115316 A TW 94115316A TW 200605881 A TW200605881 A TW 200605881A
Authority
TW
Taiwan
Prior art keywords
amino
substantially pure
phenylpyridin
pyrimidin
methylamino
Prior art date
Application number
TW094115316A
Other languages
English (en)
Inventor
El-Bdaoui Haddad
Olaf Ritzeler
David J Aldous
Paul Joseph Cox
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of TW200605881A publication Critical patent/TW200605881A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW094115316A 2004-05-12 2005-05-12 Substantially pure 2-{[2-(2-methylamino-pyrimidin-4-yl)-1H-indole-5-carbonyl]-amino}-3-(phenylpyridin-2-yl-amino)-propionic acid as an IκB kinase inhibitor TW200605881A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57014604P 2004-05-12 2004-05-12

Publications (1)

Publication Number Publication Date
TW200605881A true TW200605881A (en) 2006-02-16

Family

ID=34969825

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094115316A TW200605881A (en) 2004-05-12 2005-05-12 Substantially pure 2-{[2-(2-methylamino-pyrimidin-4-yl)-1H-indole-5-carbonyl]-amino}-3-(phenylpyridin-2-yl-amino)-propionic acid as an IκB kinase inhibitor

Country Status (23)

Country Link
EP (1) EP1747215A1 (zh)
JP (1) JP2007537266A (zh)
KR (1) KR20070011483A (zh)
CN (1) CN1950359A (zh)
AR (1) AR049274A1 (zh)
AU (1) AU2005245834A1 (zh)
BR (1) BRPI0511029A (zh)
CA (1) CA2566213A1 (zh)
EC (1) ECSP066992A (zh)
GT (1) GT200500111A (zh)
IL (1) IL178992A0 (zh)
MA (1) MA28553B1 (zh)
MX (1) MXPA06012870A (zh)
NO (1) NO20065719L (zh)
PA (1) PA8633101A1 (zh)
PE (1) PE20060269A1 (zh)
RU (1) RU2006143758A (zh)
SV (1) SV2006002111A (zh)
TN (1) TNSN06338A1 (zh)
TW (1) TW200605881A (zh)
UY (1) UY28897A1 (zh)
WO (1) WO2005113544A1 (zh)
ZA (1) ZA200608712B (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
DE102004033406A1 (de) 2004-07-10 2006-02-16 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von 2,3-Diaminopropionsäurederivaten
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2278999A4 (en) 2008-04-21 2015-04-22 Otonomy Inc EARLY TREATMENT FORMULATIONS FOR THE TREATMENT OF EARLY DISEASES AND DRESSES
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
MY159995A (en) * 2010-04-27 2017-02-15 Hutchison Medipharma Ltd Pyrimidinyl indole compounds
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2018005830A1 (en) 2016-06-29 2018-01-04 Otonomy, Inc. Triglyceride otic formulations and uses thereof
CN106588803A (zh) * 2016-11-16 2017-04-26 西南科技大学 一种制备5‑乙酰基异噁唑的新方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase

Also Published As

Publication number Publication date
MA28553B1 (fr) 2007-04-03
TNSN06338A1 (en) 2008-02-22
AR049274A1 (es) 2006-07-12
PE20060269A1 (es) 2006-05-11
IL178992A0 (en) 2007-03-08
ZA200608712B (en) 2008-06-25
KR20070011483A (ko) 2007-01-24
JP2007537266A (ja) 2007-12-20
AU2005245834A1 (en) 2005-12-01
RU2006143758A (ru) 2008-06-27
MXPA06012870A (es) 2007-02-15
EP1747215A1 (en) 2007-01-31
UY28897A1 (es) 2005-12-30
BRPI0511029A (pt) 2007-11-27
CN1950359A (zh) 2007-04-18
CA2566213A1 (en) 2005-12-11
PA8633101A1 (es) 2006-01-23
GT200500111A (es) 2006-05-09
NO20065719L (no) 2006-12-12
SV2006002111A (es) 2006-01-30
WO2005113544A1 (en) 2005-12-01
ECSP066992A (es) 2006-12-29

Similar Documents

Publication Publication Date Title
TW200605881A (en) Substantially pure 2-{[2-(2-methylamino-pyrimidin-4-yl)-1H-indole-5-carbonyl]-amino}-3-(phenylpyridin-2-yl-amino)-propionic acid as an IκB kinase inhibitor
TW200728307A (en) Novel spirochromanone derivatives
PL1753723T3 (pl) Podstawione pochodne chinoliny jako inhibitory kinezyn mitotycznych
EA200702670A1 (ru) Препарат тиенопиридинового ингибитора агрегации тромбоцитов
HK1133596A1 (en) Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
WO2009016460A3 (en) Pyrazole compounds and their use as raf inhibitors
RS52214B (en) HDAC INHIBITOR PHARMACEUTICAL FORMULATIONS
WO2005074643A3 (en) Benzamide compounds useful as rock inhibitors
MXPA05011411A (es) 1,4-diazepinas sustituidas y usos de las mismas.
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
MX2009003739A (es) Derivados de hidrobenzamida como inhibidores de hsp90.
MY147188A (en) Substituted imidazole compounds as ksp inhibitors
MY151295A (en) Pyrimidyl indoline compound
TW200745097A (en) 4-Phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors
WO2007017728A3 (en) Novel heterocyclic compounds
TW200637539A (en) CTGF inhibitors
IL181155A0 (en) 3-arylthioindole-2-carboxamide derivatives and analogs thereof as inhibitors of casein kinase i?á
WO2006051314A8 (en) Guanidine derivatives as inhibitors of ddah
WO2007045962A3 (en) Novel hdac inhibitors
TW200628153A (en) Novel compounds
MY131939A (en) New process for the industrial synthesis of the methyl diester of 5-amino-3-carboxymethyl-4-cyano-2-thiophenecarboxylic acid, and application to the synthesis of bivalent salts of ranelic acid and their hydrates
GB0212410D0 (en) Organic compounds
WO2007000392A3 (en) Chloro-substituted guanidines
MY147375A (en) Indole derivatives
TW200603805A (en) CCR-1 antagonist compounds